Name

ZyVersa Therapeutics

Legal name

ZyVersa Therapeutics, Inc.

Website

https://zyversa.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals - Inflammatory & Renal Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Clinical-stage biopharmaceutical
• Inflammasome inhibitor therapy
• Monoclonal antibody drugs
• Chronic kidney disease therapeutics
• Inflammatory disease treatment

Headquarters

HQ city

Weston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company developing proprietary drugs for inflammatory and renal diseases. Revenue expected from commercializing IC 100 and VAR 200 upon regulatory approval.

Distribution channels2 records

Marketing channels3 records

Core offering

ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company developing two proprietary first-in-class prescription drug candidates: IC 100, a humanized monoclonal IgG4 antibody that inhibits the ASC adaptor component of multiple inflammasomes to block initiation and perpetuation of the inflammatory cascade, and VAR 200, a 2HPβCD cholesterol efflux mediator that removes pathogenic cholesterol from kidney cells to treat chronic kidney diseases such as FSGS, Alport syndrome, and diabetic kidney disease. The company has not yet received regulatory approval and is pre-revenue.

Product overview

ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company with two proprietary product platforms developed from research at the University of Miami Miller School of Medicine. The company focuses on inflammatory and renal diseases. IC 100 is a humanized monoclonal antibody targeting inflammasome ASC for treatment of inflammatory diseases, with lead indication in cardiometabolic conditions. VAR 200 is a cholesterol efflux mediator targeting renal lipotoxicity for treatment of chronic kidney diseases, with lead indication in focal segmental glomerulosclerosis (FSGS), expanding into Alport syndrome and diabetic kidney disease.

Differentiator

Problem solved

Functional benefit

Brands

• IC 100: Inflammasome ASC Inhibitor - a humanized monoclonal IgG4 antibody that uniquely inhibits the adaptor ASC component of multiple types of inflammasomes for treating inflammatory disorders
• VAR 200

Products and services

• IC 100 - Inflammasome ASC Inhibitor IC 100 is a humanized monoclonal IgG4 antibody that inhibits the adaptor ASC component of multiple types of inflammasomes (12 or more), blocking inflammasome formation, activation, and initiation of the inflammatory response, and also inhibits ASC Specks to prevent perpetuation of inflammation. It is being developed to treat a broad group of inflammatory disorders including cardiometabolic conditions such as obesity, orphan renal diseases, and CNS and peripheral inflammatory diseases.
• VAR 200 - Cholesterol Efflux Mediator VAR 200 is a cholesterol efflux mediator using 2-hydroxypropyl-beta-cyclodextrin (2HPβCD) that mediates removal of pathogenic cholesterol and other lipids from kidney cells through both passive and active cholesterol efflux mechanisms, with the active ingredient accumulating in kidneys for excretion into urine. It is in development for treatment of chronic kidney diseases including focal segmental glomerulosclerosis (FSGS), Alport syndrome, and diabetic kidney disease, where it protects against structural damage, reduces proteinuria, and preserves kidney function.

Quantifiable outcome

• IC 100 demonstrated preclinical efficacy in animal models of multiple sclerosis, Parkinson's disease, stroke-related cardiovascular disease, and retinopathy of prematurity
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered strategic and core.

• Philips RespironicsstrategicStrategic or Co-development Partner · 1 May 2025Strategic partnership announced in May 2025 for inhaled therapy co-development. Philips Respironics is a respiratory care company and the partnership involves co-development of inhaled therapies.
• L&F Research LLCcoreTechnology or IntegrationTechnology/development alliance partner. L&F Research LLC is one of ZyVersa's existing technology and development alliance partners, collaborating on the development of novel therapeutics.
• InflamaCORE LLCcoreTechnology or IntegrationTechnology/development alliance partner. InflamaCORE LLC is dedicated to treating and diagnosing inflammatory injury and disease. Several of ZyVersa's scientific advisory board members are founding members of InflamaCORE.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Olatec Therapeutics: Clinical-stage company developing dapansutrile, an oral NLRP3 inflammasome inhibitor. Direct competitor to ZyVersa's IC 100 in the inflammasome/inflammation space, with overlapping cardiometabolic and inflammatory indications.
• NodThera: UK-based clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors for inflammatory and CNS diseases. Closely comparable mechanism of action and disease focus to ZyVersa's IC 100 inflammasome platform.
• Inflazome (acquired by Roche): Developed small-molecule NLRP3 inflammasome inhibitors acquired by Roche in 2020. Direct inflammasome-targeting peer; represents the path ZyVersa may follow (acquisition by big pharma) if IC 100 validates clinically.
• IFM Therapeutics (acquired by BMS): Developed NLRP3 and cGAS-STING pathway inhibitors acquired by Bristol Myers Squibb. Comparable inflammasome-focused pipeline with similar development-stage characteristics to ZyVersa, demonstrating large-pharma appetite for inflammasome assets.
• Travere Therapeutics: Commercial-stage rare disease company with sparsentan, an FDA-approved treatment for FSGS and IgA nephropathy. Most direct commercial-stage competitor to ZyVersa's VAR 200 in the renal lipotoxicity/FSGS space.
• Calliditas Therapeutics: Swedish biotech with Nefecon (Tarpeyo), an FDA-approved treatment for IgA nephropathy. Comparable clinical-stage-to-commercial renal disease player competing in the same $18B renal market targeted by VAR 200.
• Chinook Therapeutics (acquired by Novartis): Nephrology-focused biotech acquired by Novartis in 2023, developing atrasentan and other renal therapies. Direct peer in chronic kidney disease drug development; acquisition illustrates the partnership/exit dynamic ZyVersa could pursue with VAR 200.

Broad incumbents

• Vertex Pharmaceuticals: Large-cap biopharma with a growing rare renal franchise (e.g., inaxaplin for APOL1-mediated kidney disease). Broad incumbent pursuing renal indications overlapping with VAR 200's target markets, with substantially greater clinical and commercial resources.

Emerging players

• BridgeBio Pharma: Clinical-stage biopharma with a renal disease subsidiary developing treatments for rare kidney disorders. Comparable focus on chronic kidney disease with overlapping patient populations to ZyVersa's VAR 200 program.

Others

• Coherus BioSciences: Commercial-stage biopharmaceutical company co-founded by ZyVersa's CEO Stephen Glover. While focused on immuno-oncology rather than inflammasomes, the operational link and similar small-cap specialty pharma structure make it a relevant comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZyVersa Therapeutics